about
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor AntigensSynthetic biology for pharmaceutical drug discoveryAdoptive T-cell therapy for cancer: The era of engineered T cellsNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaThe biorepository portal toolkit: an honest brokered, modular service oriented software tool set for biospecimen-driven translational researchIL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.Strategies to genetically engineer T cells for cancer immunotherapy.Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cellsChimeric Antigen Receptor T-Cell Therapy for the Community OncologistThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Rationale for combining immunotherapy with chemotherapy.Mammalian synthetic biology: emerging medical applications.CAR T-cell therapy: toxicity and the relevance of preclinical models.Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.The immune system and cancer evasion strategies: therapeutic concepts.CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.Time to Akt: Superior tumor-reactive T cells for adoptive immunotherapySingle-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.Current Status of Gene Engineering Cell Therapeutics.IL-2 and Beyond in Cancer Immunotherapy.Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.CAR T-cell therapy: opportunities and challenges.Redirected T cells in cancer therapy.Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.Novel T-cell-based vaccines via arming polyclonal CD4+ T cells with antigen-specific exosomes.Engineering nanoparticles to overcome barriers to immunotherapy.Ribosome display and selection of single-chain variable fragments effectively inhibit growth and progression of microspheres in vitro and in vivo.Novel EXO-T vaccine using polyclonal CD4 T cells armed with HER2-specific exosomes for HER2-positive breast cancerPreinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
P2860
Q26774669-9DCAC585-71B8-4187-BBB7-C59BA69E2914Q26775582-40A11CBE-9957-49DE-BB81-6582B6649C31Q26800611-7800E99E-A6CE-4FB5-B188-115547BCDB37Q26992272-DB7D1CD4-FB74-4D48-A6AD-5A9DAC0DA92DQ28084879-B41E188F-900A-49D8-B8AD-0D16A7C6D404Q28387672-D7C3F38D-CC93-47BB-A918-DA4E0A480206Q30355682-D05AED13-8A25-42B8-8D16-030665777AE0Q33655849-7F96D735-8AE4-41C0-897D-F586E1400912Q33851168-F68D5455-80C9-487E-9CF0-4D2CBCA231D2Q36471557-1AC60285-88B6-4D49-B19E-6539EF9808D7Q36551673-819923D2-DEE6-42B1-9A1F-5387D57A06F6Q36727794-627F99D5-BD12-410C-B23A-AAF76D2215FEQ36884399-6E4EBB56-D77A-4CAA-8D19-57B933804A4EQ37517482-C8B0390F-EEE0-417F-A8BE-4A22DEE9EF62Q37555940-95075C73-DF4B-4D61-BD5B-40D2F9C2B28FQ38389326-2855B845-136A-461D-A4DE-90AD5CFD1D94Q38390803-966CF90A-A412-442C-97A6-22D208980BCFQ38525018-86794C88-1051-4A1F-AA7A-680EA7D1E959Q38538645-6717E70F-5278-4B3D-B2A1-85BE9D83B661Q38691172-36550D0A-4697-4AA3-B381-8F3151A7FDF1Q38758807-26E305DC-1133-45BA-8F45-02D97D501102Q38802594-99BF24EC-37AA-4ECF-AA71-E82C2BF57D05Q38913549-749AB878-E406-488D-BC3B-C3D1B4747276Q39045586-CE99C5ED-093E-447F-AFF3-E9F249759650Q41450925-C3541E1C-C3B5-4860-97AB-D9391DF98850Q41592770-C847633E-9BC6-4F60-B317-8FB52A2801ACQ45849227-730634A8-29CF-40C9-B482-F9100408D444Q47625086-2438440D-05C0-4E07-8E70-EB6A3AB85E45Q49829282-FD19F6A8-0DB7-418B-9B1E-C6CBE99B19FAQ50004232-F550B520-0896-4446-9C7D-EA78627E6951Q50027343-E6881AFD-11A3-402A-B096-3CB6609FA9C6Q50043438-86C562C2-EF5F-4996-AF4B-EDE4AB96FF7CQ50044514-FE23EF3B-5A93-4787-81E0-C4F77C00DDF8Q50535275-56606FCF-B50E-48A0-B208-B1492B4A0A2EQ52859139-3BC22D54-D91B-4158-BD26-A08B4C8FCD38Q53623298-658BD578-153A-4DA4-B6FA-F4CA8A087F88Q54991276-6DA186CF-1BCC-45AB-96B0-229C8C8A1285Q55330637-679F1B2F-03C4-42A7-91C2-1A204794488FQ58547842-E7C7108F-1536-4F27-8E7D-618A19E7C2D5Q58714103-F18CD14E-F635-4669-B499-750B1A51AEA8
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Engineered T cells for cancer therapy.
@ast
Engineered T cells for cancer therapy.
@en
Engineered T cells for cancer therapy.
@nl
type
label
Engineered T cells for cancer therapy.
@ast
Engineered T cells for cancer therapy.
@en
Engineered T cells for cancer therapy.
@nl
prefLabel
Engineered T cells for cancer therapy.
@ast
Engineered T cells for cancer therapy.
@en
Engineered T cells for cancer therapy.
@nl
P2093
P2860
P1476
Engineered T cells for cancer therapy.
@en
P2093
Bruce L Levine
Carl H June
David L Porter
Gabriela Plesa
Laura A Johnson
Stephan A Grupp
Yangbing Zhao
P2860
P2888
P304
P356
10.1007/S00262-014-1568-1
P577
2014-06-19T00:00:00Z
P5875
P6179
1037895949